Emergent Biosolutions (EBS) Tops Q4 EPS by 6c; Reaffirms FY12 Revs
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $5.08 +5.39%
Financial Fact:
Cost of product sales: 39.56M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Cost of product sales: 39.56M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Emergent Biosolutions (NYSE: EBS) reported Q4 EPS of $0.78, $0.06 better than the analyst estimate of $0.72. Revenue for the quarter came in at $107.95 million versus the consensus estimate of $109.32 million.
Emergent Biosolutions (reaffirms), seeing FY2012 revenue of $280-$300 million, versus the consensus of $304.5 million.
For earnings history and earnings-related data on Emergent Biosolutions (EBS) click here.
Emergent Biosolutions (reaffirms), seeing FY2012 revenue of $280-$300 million, versus the consensus of $304.5 million.
For earnings history and earnings-related data on Emergent Biosolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- BMO starts chip stocks coverage: Here are its preferred picks
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
